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Cannabidiol in patients 
with treatment-
resistant epilepsy 
We read with interest the results 
reported by Orrin Devinsky and 
colleagues1 of an open-label trial of 
cannabidiol in people with refractory 
epilepsy. This is a sensitive topic for 
many as there are high expectations 
for cannabidiol as a potential 
therapy for epilepsy. Some of these 
expectations have been fuelled by 
the media. Unlike other compounds, 
which are conventionally trialled 
away from the public eye, cannabidiol 
is already legally available in some 
countries. Promising case reports 
[A: references?] have encouraged 
demand for cannabidiol to be made 
available at the earliest opportunity. 
However, little is known about its 
safety and efficacy of the compound, 
making the study by Devinsky and 
colleagues timely.  
An overall seizure reduction of 
almost 50% compared with baseline is 
reported in this study. Figure 3 of the 
Article suggests that about a third of 
participants had an increased seizure 
frequency during the treatment 
period and another third had less 
than 50% seizure reduction. Patients 
often start or switch anti-epileptic 
drugs at times of an exacerbation of 
seizure frequency. Figure 3 seems to 
show a regression to the mean that 
can partly be attributed to the natural 
course of the condition, and which 
is inadequately controlled for by the 
short baseline period of this study. 
A baseline period of 4 weeks is too 
short, especially as the lowest seizure 
frequency was 11 motor seizures per 
month. A natural variation in seizure 
frequency of one or two seizures 
per month could explain a 10–20% 
change either way.
Adverse events are reported in 78% 
and serious adverse events in 30% 
of the participants in the 12-week 
treatment period. The authors 
conclude that “cannabidiol has an 
adequate safety profile”. Compared 
with other anti-epileptic drugs in 
refractory epilepsy, the number of 
serious adverse events reported seems 
high.2 This might be explained by 
epilepsy severity in this population, 
but this cannot be assessed with the 
design of this study. 
What this study does show is 
that, contrary to what many hope, 
cannabidiol is probably not the magic 
treatment for severe childhood 
epilepsy. Properly randomised and 
controlled trials are urgently needed 
to assess whether the efficacy and 
safety profile of cannabidiol is similar 
to other anti-epileptic drugs, or worse.
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